Adipokines in multiple sclerosis patients are related to clinical and radiological measures

Floor C. Loonstra(Leiden University), Merel Rijnsburger(Amsterdam Neuroscience), Eva Strijbis(Amsterdam University Medical Centers), Lodewijk R. J. de Ruiter(Leiden University), Menno M. Schoonheim(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Helga E. de Vries(Amsterdam Neuroscience), Kim Falize(Amsterdam Neuroscience), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Journal of Neurology
December 23, 2022
10.1007/s00415-022-11519-8
Cited by 15

Related Papers

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Loss of ‘Small-World’ Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity
|PLoS ONE|2010|621
Intracortical Lesions in Multiple Sclerosis: Improved Detection with 3D Double Inversion-Recovery MR Imaging
|Radiology|2005|509
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
|The Lancet Neurology|2008|484